Cell Medica, a clinical stage cellular therapeutics company engaged in
the development and delivery of cellular immunotherapy treatment
strategies for infectious disease and cancer, has announced that is has
appointed four key staff to drive forwards the Company’s activities in
the commercialisation of cell therapy treatments. The appointments will
enable the Company to achieve scale up of its cell manufacturing
operations, increase its clinical development capabilities and create a
US presence with the appointment of a Head of US Operations.
The new members of the management team include:
Dr Rainer Knaus, Senior Vice President - Rainer has over ten years
experience in the GMP manufacturing of cell therapies and managed the
commercial launch of the first stem cell product in Germany. Rainer is
overseeing European activities including manufacturing, product
development and regulatory requirements.
Mike Ramsay, Head of US Operations - Mike joins Cell Medica from his
position as Senior Vice President of Operations at Cell Genesys. Mike
has over 20 years experience in the US biotech industry and is leading
the Company’s US business activities. Mike will establish the US
business infrastructure which includes R&D partnerships with leading
academic research institutions.
Karen Hodgkin, Head of Clinical Development – Karen has 25 years
experience in clinical trials management across a range of therapeutic
areas. Karen is managing the Company’s confirmatory clinical trial
currently running across 14 major hospitals in the UK.
Tina Crombie, Head of Business Administration – Tina’s experience in IP
management, project management and business administration includes
previous positions in academic, public and commercial science-based
organizations.